The tri-nucleotide repeat expansion underlying Huntington disease (HD) results in corticostriatal synaptic dysfunction and subsequent neurodegeneration of striatal medium spiny neurons (MSNs). HD is a devastating autosomal dominant disease with…
The article by Nygaard and others (2016) proposes that applying batch correction approaches to microarray data from studies with unbalanced designs may inadvertently exaggerate the differences observed. In seeking to illustrate their point, Nygaard and others (2016) utilized…
Although pancreatic cancer is increasing in incidence, therapeutic options remain limited. Treatment with gemcitabine or a gemcitabine combination therapy is most common, although current combination therapies are challenged by toxicity….
Abstract Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the…
Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism is insufficient to explain…
Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical…
Background and aims: Copaxone ® is a non-biological complex drug (NBCD) for the treatment of multiple sclerosis. Recently, differently manufactured follow-on glatiramoid drug products (FOGAs) purported to be equivalent to…
Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell…
Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical…
Pancreatic cancer has an estimated survival rate of only 5-6% (Siegel et al. 2015). The difficulty in early detection methods compounded by clinical trial failures precipitates the need for innovative…
© 2025 Immuneering Corporation.
